131 related articles for article (PubMed ID: 38140101)
1. Enhancing Immunogenicity of a Thermostable, Efficacious SARS-CoV-2 Vaccine Formulation through Oligomerization and Adjuvant Choice.
Khan MS; Jakob V; Singh R; Rajmani RS; Kumar S; Lemoine C; Kleanthous H; Ringe RP; Dubois PM; Varadarajan R
Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140101
[TBL] [Abstract][Full Text] [Related]
2. Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD).
Kumru OS; Bajoria S; Kaur K; Hickey JM; Van Slyke G; Doering J; Berman K; Richardson C; Lien H; Kleanthous H; Mantis NJ; Joshi SB; Volkin DB
Hum Vaccin Immunother; 2023 Aug; 19(2):2264594. PubMed ID: 37932241
[TBL] [Abstract][Full Text] [Related]
3. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
[TBL] [Abstract][Full Text] [Related]
4. Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants.
Mittal N; Kumar S; Rajmani RS; Singh R; Lemoine C; Jakob V; Bj S; Jagannath N; Bhat M; Chakraborty D; Pandey S; Jory A; Sa SS; Kleanthous H; Dubois P; Ringe RP; Varadarajan R
NPJ Vaccines; 2023 Oct; 8(1):161. PubMed ID: 37880298
[TBL] [Abstract][Full Text] [Related]
5. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
Front Immunol; 2022; 13():974364. PubMed ID: 36159845
[TBL] [Abstract][Full Text] [Related]
6. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
[TBL] [Abstract][Full Text] [Related]
7. Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity.
Nanishi E; Borriello F; O'Meara TR; McGrath ME; Saito Y; Haupt RE; Seo HS; van Haren SD; Brook B; Chen J; Diray-Arce J; Doss-Gollin S; Leon M; Chew K; Menon M; Song K; Xu AZ; Caradonna TM; Feldman J; Hauser BM; Schmidt AG; Sherman AC; Baden LR; Ernst RK; Dillen C; Weston SM; Johnson RM; Hammond HL; Mayer R; Burke A; Bottazzi ME; Hotez PJ; Strych U; Chang A; Yu J; Barouch DH; Dhe-Paganon S; Zanoni I; Ozonoff A; Frieman MB; Levy O; Dowling DJ
bioRxiv; 2021 May; ():. PubMed ID: 34031655
[TBL] [Abstract][Full Text] [Related]
8. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
[TBL] [Abstract][Full Text] [Related]
9. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Immunogenicity and Protective Efficacy of a
Ramakrishnan A; Schumack NM; Gariepy CL; Eggleston H; Nunez G; Espinoza N; Nieto M; Castillo R; Rojas J; McCoy AJ; Beck Z; Matyas GR; Alving CR; Guerry P; Poly F; Laird RM
mSphere; 2019 May; 4(3):. PubMed ID: 31043512
[No Abstract] [Full Text] [Related]
11. Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018
Bajoria S; Kumru OS; Doering J; Berman K; Slyke GV; Prigodich A; Rodriguez-Aponte SA; Kleanthous H; Love JC; Mantis NJ; Joshi SB; Volkin DB
Vaccines (Basel); 2023 May; 11(6):. PubMed ID: 37376419
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations.
Siriwattananon K; Manopwisedjaroen S; Shanmugaraj B; Prompetchara E; Ketloy C; Buranapraditkun S; Tharakhet K; Kaewpang P; Ruxrungtham K; Thitithanyanont A; Phoolcharoen W
Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358160
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
14. Designing Adjuvant Formulations to Promote Immunogenicity and Protective Efficacy of
Techawiwattanaboon T; Courant T; Brunner L; Sathean-Anan-Kun S; Krangvichian P; Iadsee N; Nakornpakdee Y; Sangjun N; Komanee P; Collin N; Ruxrungtham K; Patarakul K
Front Cell Infect Microbiol; 2022; 12():918629. PubMed ID: 35782116
[TBL] [Abstract][Full Text] [Related]
15. A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine.
Liu D; An C; Bai Y; Li K; Liu J; Wang Q; He Q; Song Z; Zhang J; Song L; Cui B; Mao Q; Jiang W; Liang Z
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146661
[TBL] [Abstract][Full Text] [Related]
16. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern.
Renner TM; Akache B; Stuible M; Rohani N; Cepero-Donates Y; Deschatelets L; Dudani R; Harrison BA; Baardsnes J; Koyuturk I; Hill JJ; Hemraz UD; Régnier S; Lenferink AEG; Durocher Y; McCluskie MJ
Front Immunol; 2023; 14():1182556. PubMed ID: 37122746
[TBL] [Abstract][Full Text] [Related]
17. Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine.
O'Donnell JS; Isaacs A; Jakob V; Lebas C; Barnes JB; Reading PC; Young PR; Watterson D; Dubois PM; Collin N; Chappell KJ
Front Immunol; 2022; 13():976968. PubMed ID: 36119058
[TBL] [Abstract][Full Text] [Related]
18. Squalene in oil-based adjuvant improves the immunogenicity of SARS-CoV-2 RBD and confirms safety in animal models.
Choque-Guevara R; Poma-Acevedo A; Montesinos-Millán R; Rios-Matos D; Gutiérrez-Manchay K; Montalvan-Avalos A; Quiñones-Garcia S; Cauti-Mendoza MG; Agurto-Arteaga A; Ramirez-Ortiz I; Criollo-Orozco M; Huaccachi-Gonzales E; Romero YK; Perez-Martinez N; Isasi-Rivas G; Sernaque-Aguilar Y; Villanueva-Pérez D; Ygnacio F; Vallejos-Sánchez K; Fernández-Sánchez M; Guevara-Sarmiento LA; Fernández-Díaz M; Zimic M;
PLoS One; 2022; 17(8):e0269823. PubMed ID: 35998134
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
Phoolcharoen W; Shanmugaraj B; Khorattanakulchai N; Sunyakumthorn P; Pichyangkul S; Taepavarapruk P; Praserthsee W; Malaivijitnond S; Manopwisedjaroen S; Thitithanyanont A; Srisutthisamphan K; Jongkaewwattana A; Tomai M; Fox CB; Taychakhoonavudh S
Vaccine; 2023 Apr; 41(17):2781-2792. PubMed ID: 36963999
[TBL] [Abstract][Full Text] [Related]
20. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
